Some GLP-1s Achieve More Weight Loss Than Others: Study By Dennis Thompson HealthDay ... shows that the widely-known drugs tirzepatide (Zepbound) and semaglutide (Wegovy) are both safe and ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

but still less than what’s been seen with competitor Eli Lilly’s Zepbound. In a 72-week study, a 7.2-milligram dose of Wegovy led patients with obesity to lose 18.7% of their weight ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Zepbound (tirzepatide ... resulted in significant and sustained weight loss. The study, which had support from the drug’s manufacturer, found that tirzepatide resulted in a mean total body ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Wegovy: FDA-approved for the management of obesity in June 2021, this medication has gained widespread attention for its effectiveness in supporting weight loss. Zepbound: Recently FDA-approved in ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...